Public healthcare costs are rising. Governments need to get them under control. In Europe, that means the systematic use of health technology assessments (HTA) and reference pricing. The US, on the other hand, focuses on comparative effectiveness research (CER) to identify drugs that maximise clinical efficacy, minimise clinical harm and are more in tune with individual needs. Vastly different solutions—but are they working?
 
 Report Overview
 In Pricing and Reimbursement Trends in the US: Impact of Comparative Effectiveness Research and Cost-Effectiveness Analysis, FirstWord Dossier lays bare the US model by defining comparative effectiveness research and exploring its limitations with regards to drug trials. The report expertly examines direct versus indirect cost effectiveness analysis, the role of key government institutions and managed care organisations and the impact such research is having on blockbuster drugs. Based on au courant research, expert interviews and several compelling case studies, the report takes a critical look at US policy decisions and trends and offers a clear, uncluttered view of the US drug reimbursement system. http://www.bharatbook.com/market-research-reports/healthcare-market-research-report/pricing-and-reimbursement-trends-in-the-us-impact-of-comparative-effectiveness-research-and-cost-effectiveness-analysis.html
 
 Key Report Features
 * Wide-ranging analysis of US drug and reimbursement policies and how they differ from European models
 * Review of the use of CER in the US, with particular attention to Medicaid and Medicare
 * Up-to-date insight into the role of branded biologics and biosimilars in the US market
 * Insight into cost-containing managed care tools
 * Examination of the benefits and drawbacks of head-to-head trials and combination therapy
 * Analysis of future CER proposals and their implications
 * Market Research Reports
 
 Key Benefits
 * Expert insight from ten industry voices on the effect of CER and CEA on the US system of drug reimbursement
 * In-depth examination of pertinent policy decisions and trends in the US pharmaceutical industry, explaining the utilisation of CER and direct versus indirect CEA
 * Multiple case studies and comprehensive references to key literature
 
 Key Questions Asked
 * How does the US now control prescription drugs costs and what roles do reimbursement and pricing play?
 * How are US and European models similar and how do they differ?
 * How do branded pharmaceutical cost considerations influence reimbursement decisions and policy at the federal level in the US, as government costs outpace government revenue?
 * What are the implications of these trends for pharma and how will it respond?
 
 Who Would Benefit From This Report?
 * Global health economists
 * Global HTA directors
 * Managed care/market directors
 * Pricing and reimbursement managers
 * Marketing, brand and sales managers
 * Business development executives
 * Regulatory and government affairs professionals
 
 For more information kindly visit :
 Pricing and Reimbursement Trends in the US: Impact of Comparative Effectiveness Research and Cost-Effectiveness Analysis
 
 Or
 
 Bharat Book Bureau
 Tel: +91 22 27810772 / 27810773
 Fax: + 91 22 27812290
 Email: info@bharatbook.com
 Website: www.bharatbook.com
 Follow us on twitter: http://twitter.com/#!/Sandhya3B